This retrospective study investigated the efficacy of bevacizumab in refractory brain edema caused by brain metastasis from lung cancer and colon cancer.

A total of 72 patients with refractory brain edema were divided into the lung cancer and colon cancer groups according to their primary tumor. All patients received a single bevacizumab treatment for refractory brain edema. MRI was performed 1 week before the treatment and 4 weeks after the treatment. The edema and tumor volumes were calculated using imaging modalities.

After a single bevacizumab treatment, the refractory brain edema of 61 patients was controlled, and the clinical symptoms of 65 patients were improved. The average edema volume before treatment was 201,708.97 ± 61,426.04 mm³, which has decreased to 116,947.01 ± 43,879.16 mm³ after treatment (P < 0.05). After treatment, the edema index decreased from 25.97 ± 7.15 to 17.32 ± 5.24 (P < 0.05).We found that brain edema was controlled in 40 patients (93.02%) in the lung cancer group and 21 patients (72.41%) in the colon cancer group (P<0.05). In addition, 22 patients (88.00%) in the radiotherapy group achieved edema control, compared to 39 (82.98%) in the non-radiotherapy group (P>0.05). Nine patients experienced hypertension after treatment, two patients exhibited decreased platelet counts, and no hemorrhage cases were observed.

Bevacizumab can significantly alleviate refractory brain edema, and there is a significant difference in the efficacy of bevacizumab on refractory brain edema caused by brain metastasis from lung and colon cancers.

这项回顾性研究调查了贝伐单抗在肺癌和结肠癌脑转移引起的难治性脑水肿中的疗效。

将72例难治性脑水肿患者按原发肿瘤分为肺癌组和结肠癌组。所有患者均接受单一贝伐单抗治疗难治性脑水肿。治疗前1周和治疗后4周进行MRI检查。使用成像方式计算水肿和肿瘤体积。

单次贝伐单抗治疗后，61例难治性脑水肿得到控制，65例患者临床症状得到改善。治疗前平均水肿体积为201,708.97 ± 61,426.04 mm ³，已降至116,947.01 ± 43,879.16 mm ³治疗后（P < 0.05）。治疗后水肿指数由25.97±7.15下降至17.32±5.24（P<0.05）。我们发现肺癌组40例（93.02%）脑水肿得到控制，结肠21例（72.41%）脑水肿得到控制。癌组（P<0.05）。此外，放疗组22例（88.00%）患者水肿得到控制，非放疗组为39例（82.98%）（P>0.05）。9例患者治疗后出现高血压，2例血小板减少，无出血病例。

贝伐单抗可显着缓解难治性脑水肿，贝伐单抗对肺癌和结肠癌脑转移所致难治性脑水肿的疗效存在显着差异。